SCHEMBL6490977

SCHEMBL6490977

O=C(O)c1cncnc1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 4/20 0.49
CSNK2B P67870 4/20 0.49
KMO O15229 2/20 0.44
USP2 O75604 2/20 0.43
CYP1A2 P05177 2/20 0.43
TSHR P16473 1/20 0.43
CDH1 P12830 1/20 0.42
APC P25054 1/20 0.42
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968241 0.84 LDHA (0.44) USP2CYP1A2TSHRKDM4ELMNA
SCHEMBL1966535 0.83 KMO (0.49) CSNK2A2CSNK2BKMOTSHRSMN1; SMN2
SCHEMBL1972138 0.83 GAA (0.47) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL1968017 0.83 KDM4E (0.44) CSNK2A2CSNK2BUSP2CYP1A2NPC1
SCHEMBL26081233 0.83 KDM4E (0.45) CSNK2A2CSNK2BKDM4ESMN1; SMN2LMNA
SCHEMBL1967616 0.83 KMO (0.57) KMOXDHSLC22A12
SCHEMBL8579235 0.81 CYP1A2 (0.42) CSNK2A2CSNK2BUSP2CYP1A2TSHR
SCHEMBL6640146 0.81 SLC6A3 (0.50) CSNK2A2CSNK2BUSP2CYP1A2TSHR
SCHEMBL1970118 0.81 KMO (0.50) CSNK2A2CSNK2BKMOUSP2CYP1A2
SCHEMBL10840568 0.80 KMT2A (0.51) USP2CYP1A2KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed
EP-1383760-A1 BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-28 EP disclosed
WO-2002090347-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 CSNK2A2 617/4885CSNK2B 413/4885KMO 1583/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CSNK2A2 342/4885CSNK2B 271/4885KMO 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.